The comparison of Buprenorphine and Ketorolac Analgesic Effect in Patients with Renal Colic

The comparison of Sublingual Buprenorphine and IV Ketorolac Analgesic Effect in Patients with Renal Colic Presented to Emergency Department

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015041421773N1

Enrollment

Registered

2015-05-09

Start date

2015-06-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic. urinary calculus, unspecified

Interventions

Intervention 1: Drug intervention carry out in two groups as each group, resives drug and placebo. Group1: sublingual buprenorphine (tab 0.4 mg) with IV sterile water (placebo). Intervention 2: Drug i

Treatment - Drugs

Drug intervention carry out in two groups as each group, resives drug and placebo. Group1: sublingual buprenorphine (tab 0.4 mg) with IV sterile water (placebo)

Drug intervention carry out in two groups as each group, resives drug and placebo. Group2: IV ketorolac (30 mg) with sublingual placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: patient with both gender? Age through 18-55 years old? Severity pain of renal colic in Visual Pain Analog Scale must be 3-10. Clnical Criteria: Nephrolithiasis history? Severity pain in loin region , Dysuria, Laboratory criteria: Urinary Analysis (+) Imaging Criteria: Confirm of stone with Computed Tomography without contrast or sonography. Exclusion Criteria: Decreased level of consciousness? Cardiac problems? Chronic Renel diseases? Hepatic and Respiratory diseases? Allergy to Opioieds? Resiving of analgesic drug in passed 6 hours? History of seizure? Pregnancy? Addiction? Abdominal tenderness? History or active Gastrointestinal Bleeding.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: 0, 20, 40 and 60 minets after drug intervention. Method of measurement: Visual Pain Analog Scale.	—

Secondary

Measure	Time frame
Adverse Effects. Timepoint: 0, 20, 40 and 60 minets after drug intervention. Method of measurement: Clinical examination, Observation and asking from patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Javad Mozafari

Emergency Department- Medicine faculty- Jundishapour University of Medical Sciences

mozafari.taha@yahoo.comdezham58@yahoo.com+98 61 3374 3079

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 26, 2026